m6A-centered Drug Response Information

General Information of the Drug (ID: M6APDG03551)
Name
HYDAMTIQ
Synonyms
PARP-1 inhibitor (brain ischemia), University of Perugia
    Click to Show/Hide
Status
Investigative
TTD Drug ID
D0CA2S
Target Gene(s) and Their Upstream m6A Regulator, Together with the Effect of Target Gene(s) in Drug Response
The target genes involved in drug-target interaction (such as drug-metabolizing enzymes, drug transporters and therapeutic targets) and drug-mediated cell death signaling (including modulating DNA damage and repair capacity, escaping from drug-induced apoptosis, autophagy, cellular metabolic reprogramming, oncogenic bypass signaling, cell microenvironment, cell stemness, etc.) could be regulated by m6A regulator(s) and affected their corresponding drug response. You can browse detailed information on drug-related target gene(s) mediated by m6A regulators.
Poly [ADP-ribose] polymerase 1 (PARP1)
Methyltransferase-like 3 (METTL3)
In total 1 mechanisms lead to this potential drug response
 Regulator Info 
Response Summary Poly [ADP-ribose] polymerase 1 (PARP1) is a therapeutic target for HYDAMTIQ. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of HYDAMTIQ through regulating the expression of Poly [ADP-ribose] polymerase 1 (PARP1). [1], [2]
YTH domain-containing family protein 1 (YTHDF1)
In total 1 mechanisms lead to this potential drug response
 Regulator Info 
Response Summary Poly [ADP-ribose] polymerase 1 (PARP1) is a therapeutic target for HYDAMTIQ. The YTH domain-containing family protein 1 (YTHDF1) has potential in affecting the response of HYDAMTIQ through regulating the expression of Poly [ADP-ribose] polymerase 1 (PARP1). [1], [2]
References
Ref 1 METTL3 promotes oxaliplatin resistance of gastric cancer CD133+?stem cells by promoting PARP1 mRNA stability. Cell Mol Life Sci. 2022 Feb 18;79(3):135. doi: 10.1007/s00018-022-04129-0.
Ref 2 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 2771).